Depression During Perimenopause: Symptoms, Risk, and Treatment
Updated: 3 days ago
Author: Angela Bogdanova · Published: October 18, 2026 · Editorial Policy
Research cluster: Cluster Perinatal and Reproductive Mental Health · Written by Artificial Sapiens
What is depression during perimenopause?
Depression during perimenopause refers to clinically significant depressive symptoms or a depressive disorder occurring during the transition toward menopause. Perimenopause is a reproductive stage defined primarily by changes in menstrual cycling and ovarian hormone patterns; depression is a clinical condition evaluated by its emotional, cognitive, physical, behavioral, and functional features. The two can coincide, interact, and sometimes amplify each other. A person with persistent low mood, loss of pleasure, hopelessness, or impaired everyday functioning deserves a depression assessment whether or not hot flashes, irregular periods, or other menopause symptoms are present. Maki et al., clinical recommendations; NIMH, depression.
The menopause transition is associated with a measurable increase in the likelihood of depression at the population level, although individual experiences range from stable emotional well-being to severe illness. A 2024 systematic review and meta-analysis of prospective cohorts reported higher odds of depressive symptoms or diagnoses during perimenopause than premenopause (odds ratio 1.40, 95% confidence interval 1.21–1.61). This is a relative comparison between groups, not a prediction that any particular individual will develop depression. The authors emphasized differences in definitions, measures, and study populations. Badawy et al., 2024.
Effective care begins with two assessments conducted together: the clinical course of depressive symptoms and the reproductive, physical, and psychosocial circumstances surrounding them. Identifying a menopause transition can guide treatment of vasomotor symptoms and sleep disturbance; diagnosing a depressive disorder directs evidence-based mental health care. An individualized plan may include psychotherapy, antidepressant medication when indicated, treatment of distressing menopause symptoms, sleep interventions, coordinated follow-up, and specialist care for complex presentations. Maki et al., 2019; NICE NG23.
Understanding the menopause transition
Perimenopause, menopause, and early postmenopause
Menopause is identified retrospectively after twelve consecutive months without menstrual bleeding when there is no other physiological or pathological explanation. Perimenopause encompasses the transition preceding that point and, in broader clinical usage, often includes the first year following the final menstrual period. The formal Stages of Reproductive Aging Workshop framework (STRAW+10) defines an early transition marked by persistent variation of approximately seven or more days in consecutive cycle length and a late transition associated with an interval of at least sixty days without bleeding. These are clinical staging concepts, not a way to diagnose depression. Harlow et al., STRAW+10.
Ovarian estradiol and progesterone production becomes increasingly variable through the transition. Estradiol levels can rise sharply and fall unpredictably before they eventually settle at lower postmenopausal levels. Follicle-stimulating hormone (FSH) is also variable. In many people aged forty-five or older with characteristic cycle changes and vasomotor symptoms, the clinical history is more useful for identifying perimenopause than a single hormone measurement. Hormonal contraception, hysterectomy, ovarian surgery, thyroid illness, and other conditions may complicate staging and require individualized evaluation. STRAW+10; NICE NG23.
Why reproductive stage matters to mental health
The transition changes more than menstrual timing. Hot flashes and night sweats can fragment sleep. Genitourinary symptoms, sexual discomfort, migraine, changing bleeding patterns, and fatigue may affect quality of life. At the same time, people often face demanding work, caregiving, changing relationships, bereavement, financial pressure, or chronic health conditions. These intersecting exposures should be assessed in their own right. A biological transition does not make an individual's account of distress reducible to hormones. The Menopause Society, Mental Health; Maki et al., 2019.
Depressive symptoms, depressive episodes, and ordinary emotional variation
Symptoms that warrant attention
Common manifestations include persistent sadness, emptiness, tearfulness, irritability, loss of interest in formerly meaningful activities, loss of motivation, guilt, diminished self-worth, difficulty concentrating or deciding, changes in appetite or weight, psychomotor slowing or agitation, fatigue, sleep disturbance, and thoughts about death. Some people chiefly describe exhaustion, physical discomfort, withdrawal, or the sense that they no longer recognize their usual emotional responses. Severity is judged from the entire picture: duration, frequency, intensity, impairment, safety, and clinical context. NIMH, Depression.
Vasomotor symptoms and insomnia overlap with several features of depression. Night sweats may explain interrupted sleep and daytime fatigue without a depressive episode. Conversely, persistent loss of pleasure, hopelessness, worthlessness, and suicidal thinking call for direct assessment even when sleep disruption is prominent. Depression can also cause awakening, fatigue, and concentration problems independently of menopause symptoms. Asking how each symptom began and how it changes over time prevents one problem from concealing another. Maki et al., 2019.
When does low mood become major depression?
A major depressive episode typically requires a constellation of symptoms present most of the day, nearly every day, for at least two weeks, including depressed mood or loss of interest or pleasure, together with clinically significant distress or functional impairment. Diagnosis also requires consideration of substance effects, medical conditions, and prior manic or hypomanic episodes. Subthreshold depressive symptoms may still be burdensome and respond to proportionate care. A two-week duration is a diagnostic convention, not a reason to postpone evaluation of an emerging crisis. NIMH, Depression; NICE NG222.
Ordinary emotional variation includes brief sadness or frustration that changes with circumstances and leaves a person's basic capacity to function intact. Menopause-associated distress may be considerable even when formal depression criteria are not met. Clinical practice therefore distinguishes well-being, situational distress, depressive symptoms, a syndromal depressive disorder, and urgent danger. These categories support different levels of intervention and should not be conflated with a single screening score.
Is irritability depression?
Irritability is common during the menopause transition and can occur with sleep loss, anxiety, interpersonal stress, or depression. In an adult it is not, by itself, sufficient to establish major depressive disorder. Its significance increases when accompanied by sustained anhedonia, pervasive negative thinking, suicidal ideation, or declining function. A clinician should also ask about episodic irritability with unusually increased energy, reduced need for sleep, impulsive decisions, or elevated mood, because such episodes can indicate bipolar-spectrum illness and change medication safety decisions.
How much does perimenopause increase depression risk?
What longitudinal studies actually show
Observational cohorts follow people over reproductive stages rather than comparing only different age groups at one moment. The Study of Women's Health Across the Nation (SWAN) contributed evidence that major depressive episodes can become more likely during the transition and early postmenopause. A Pittsburgh-site analysis with structured psychiatric interviews found substantially higher relative odds of episodes in these stages than in premenopause; a history of major depression was itself a strong predictor across observation. Effects varied by model and sample, which is why a result from one cohort should not be treated as the universal probability of illness. Bromberger et al., 2011.
A later synthesis offers a more conservative pooled estimate. Badawy and colleagues reviewed seventeen prospective cohorts involving 16,061 participants, with seven papers contributing 9,141 participants to their quantitative meta-analysis. Their pooled odds ratio of 1.40 combines studies measuring both depressive symptoms and depression diagnoses, so it must not be translated into a 40% increase in the absolute probability of diagnosed major depression. The review did not identify a statistically significant increase for postmenopause versus premenopause across the studied outcomes. Badawy et al., 2024.
Absolute risk and clinical meaning
An odds ratio describes how odds compare between groups, rather than the number of people who become depressed. If baseline risk differs across populations, the corresponding absolute increase differs as well. The clinical conclusion is to remain attentive to symptoms and risk factors, particularly among those with prior depressive illness, while avoiding deterministic predictions. Population risk is useful for planning access to assessment; it does not establish that a specific episode was caused by a particular hormone change.
Who may be especially vulnerable?
A previous depressive episode, including a history of mood disorders related to reproductive transitions, increases concern about recurrence. Other clinically relevant factors include significant sleep disruption, distressing hot flashes, stressful life events, trauma exposure, limited social support, persistent pain, chronic medical illness, and socioeconomic pressures. Relationships between these factors vary across studies, and many operate bidirectionally. Depression may disturb sleep; poor sleep may worsen mood; both may be intensified by night sweats. The most useful risk assessment investigates the individual's circumstances instead of treating a list of correlates as a diagnosis. Maki et al., 2019; The Menopause Society.
A prior episode is an important signal but is not a prerequisite. First-onset depressive episodes can occur during midlife and deserve the same quality of assessment and treatment as recurrent illness. The absence of a psychiatric history does not justify attributing substantial suffering solely to a normal reproductive transition.
Biological and psychosocial mechanisms
Sensitivity to fluctuating ovarian hormones
Estradiol acts through receptors in multiple brain systems involved in mood, stress regulation, sleep, temperature regulation, and cognition. Changes in ovarian hormones may affect monoaminergic signaling and other neurobiological pathways, but mechanistic models remain incomplete. A central hypothesis proposes that some people are particularly sensitive to hormonal fluctuation or withdrawal during the transition. In this model, vulnerability depends on an individual's response to change, rather than on a single universally low estrogen threshold. This is plausible and supported by converging clinical observations, but a definitive biomarker for hormone-sensitive depression is unavailable. The Menopause Society; Maki et al., 2019.
Hormone levels measured once are especially poor proxies for this sensitivity because estradiol and FSH can change over short intervals. A normal laboratory result cannot rule out either perimenopause or depression. Likewise, a low estradiol value cannot prove the cause of a depressive episode. Hormonal measures sometimes assist a separate endocrine question, but depression remains a clinical diagnosis.
Sleep, vasomotor symptoms, and the stress system
Night sweats and hot flashes may lead to repeated awakenings, reduced sleep continuity, worry about the next night, daytime irritability, and lower emotional resilience. At the same time, depression can itself disturb sleep. Managing hot flashes or insomnia may therefore improve well-being, energy, and certain depressive symptoms without necessarily resolving a major depressive disorder. Treatment outcomes should be assessed separately for vasomotor symptoms, sleep quality, and depression severity. NICE NG23; The Menopause Society 2023 nonhormone statement.
Life-course and social context
The menopause transition occurs within a changing life course. Relationships, aging parents, children, occupational demands, identity, discrimination, disability, bereavement, and access to care shape the experience of physical and emotional symptoms. Clinical evaluation should ask what the patient values, which circumstances have changed, and what supports or pressures surround them. Social explanations and biological models can both contribute; neither supplies a complete account of a particular person's illness. Research cohorts have important differences in racial, socioeconomic, and geographic representation that limit the simple transfer of average estimates to all populations.
Clinical assessment: a coordinated approach
The clinical interview
An assessment begins by establishing symptom onset and duration, depressive and anxiety features, degree of functional impairment, current safety, relevant medications and substances, physical illness, and past response to treatment. It should examine prior depression, episodes of elevated or irritable mood with increased energy, psychiatric hospitalization, previous self-harm, and family psychiatric history. Menstrual history covers cycle changes, last menstrual period, contraception, pregnancies when relevant, surgery, and vasomotor or genitourinary symptoms. Clinicians can ask about sleep, sexual health, pain, caregiver burden, work, intimate-partner safety, and the patient's own explanatory model. Maki et al., 2019; NICE NG222.
The clinician should determine whether depressed mood occurs primarily after nights of disturbed sleep, varies episodically with reproductive symptoms, or continues throughout the day across different circumstances. These patterns inform care but do not substitute for formal diagnostic criteria. A history of reproductive sensitivity may be useful, while retrospective symptom recall can be imprecise.
Screening tools and their limits
The Patient Health Questionnaire-9 (PHQ-9) can help identify depressive symptoms, quantify severity, and monitor change. Short initial questionnaires and other validated instruments may be suitable according to setting, language, and patient needs. A high score indicates the need for clinical assessment; it is not a standalone diagnosis. Sleep, energy, and concentration items may be elevated partly because of menopause symptoms or other conditions. Conversely, a seemingly modest total score should never override direct disclosure of suicidal thoughts, severe functional decline, mania, or psychosis. Clinicians must ask what each endorsed symptom means to the individual. NIMH, Depression; NICE NG222.
Repeated measurements are most useful when tied to a treatment plan and interpreted with an interview. Changes in scores can reflect improved sleep, reduced hot flashes, medication effects, psychotherapy, shifting life conditions, or several changes together. Follow-up must track functioning and safety as well as symptom totals.
Menopause identification and laboratory investigations
For many individuals aged forty-five or older with typical symptoms, perimenopause can be identified clinically. FSH and estradiol fluctuate and are generally unreliable as single tests of transition stage. Pregnancy testing, thyroid function, a blood count, or other investigations may be warranted according to history, bleeding changes, fatigue, medication use, and physical findings. Decisions about laboratory tests should answer a specific clinical question instead of relying on a generic menopause-depression panel. NICE NG23; STRAW+10.
Unusually heavy or abnormal uterine bleeding also requires appropriate gynecologic assessment. Mood changes should not divert attention from anemia, thyroid disease, medication adverse effects, or other treatable conditions. People with early menopause, induced menopause, or complex hormone exposure may need specialist assessment.
Differential diagnosis: what else can resemble perimenopausal depression?
Vasomotor-symptom-related fatigue and insomnia
Hot flashes, night sweats, and fragmented sleep can produce exhaustion, irritability, and poor concentration. If these occur without persistent depressed mood or loss of interest, a separate major depressive episode may be absent. Depression and menopause symptoms often coexist, however, so treating one should not end the assessment of the other.
Anxiety disorders and trauma-related conditions
Generalized anxiety disorder, panic symptoms, and trauma-related distress may cause sleep disturbance, restlessness, concentration problems, somatic arousal, and reduced well-being. Depression may be comorbid. The clinician should assess persistent uncontrollable worry, panic attacks, avoidance, traumatic reminders, and the presence or absence of anhedonia and sustained low mood. Treatment planning follows the identified disorders and the patient's preferences.
Bipolar depression and hypomania
Bipolar depression can resemble unipolar major depression during a low-mood episode. A history of hypomania or mania changes the diagnosis and treatment strategy. Warning features include distinct periods of unusually increased energy or activity, markedly reduced need for sleep without fatigue, elevated or expansive mood, racing thoughts, pressured speech, grandiosity, and risky behavior. New agitation and sleeplessness after starting an antidepressant or hormones should be evaluated, particularly in someone with bipolar vulnerability. Antidepressant monotherapy may be inappropriate in bipolar illness, and psychiatric consultation is important. NICE NG222.
Medical and medication-related causes
Thyroid dysfunction, anemia, sleep apnea, chronic pain, inflammatory conditions, substance use, and adverse medication effects can contribute to depressive-like symptoms or coexist with major depression. Clinicians should review alcohol and cannabis use, sedating and activating medications, recent medication changes, and any supplements. Appropriate testing follows clinical indicators; a medical finding and a depressive disorder can both merit treatment.
Menstrual-cycle conditions and premenstrual exacerbation
Premenstrual dysphoric disorder (PMDD) has a characteristic timing pattern, with symptoms recurring during the late luteal phase and improving around menstruation, established through prospective daily ratings. Premenstrual exacerbation describes worsening of an underlying disorder before menstruation while symptoms remain present at other times. Irregular cycles during perimenopause can complicate tracking. Neither PMDD nor premenstrual exacerbation is interchangeable with a sustained depressive disorder during menopause transition. If cycling remains observable, prospective symptom records can inform distinctions. Maki et al., 2019.
Treatment principles and shared decisions
A treatment plan addresses the level of depression, coexisting menopause symptoms, safety, patient preferences, previous outcomes, medical contraindications, and access to care. Psychotherapy and antidepressants are established treatments for major depressive disorder during perimenopause. Menopausal hormone therapy (MHT) has important uses in vasomotor-symptom care and may improve depressive symptoms for some individuals, but the available evidence does not establish it as a universal substitute for depression-specific treatment. Maki et al., 2019; NICE NG23; Li et al., 2026.
Psychotherapy for depression
Evidence-based psychological treatments include cognitive behavioral therapy (CBT), behavioral activation, and interpersonal psychotherapy according to depression severity and availability. CBT examines the links among interpretations, avoidance, mood, and behavior and develops adaptive coping and activity patterns. Behavioral activation supports re-engagement with rewarding or meaningful experiences. Interpersonal therapy focuses on relationship transitions, grief, conflict, and social roles, issues that may become especially salient at midlife. These therapies are selected for the depressive disorder itself rather than for a particular estrogen level. NICE NG222.
Menopause-specific CBT is a related but distinct intervention designed to help manage hot flashes, associated distress, sleep, and menopause-related depressive symptoms. NICE recommends considering menopause-specific CBT for vasomotor symptoms, sleep problems, and depressive symptoms associated with menopause. For a person who meets diagnostic criteria for major depression, therapy should still match depression-treatment recommendations; menopause-focused techniques can be integrated when relevant. NICE NG23.
Antidepressant medication
Selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and other evidence-based antidepressants may be appropriate for moderate, severe, recurrent, or persistent depression, with choices tailored to symptom patterns, past benefit, side effects, interactions, medical history, and patient preference. Some SSRIs and SNRIs also reduce vasomotor symptoms at suitable doses, but relief of hot flashes and treatment of major depression involve different treatment aims and sometimes different doses. The choice of one medication to address two problems should be deliberate and clinically reviewed. Maki et al., 2019; The Menopause Society 2023 statement.
Antidepressant response takes monitoring over weeks. Initial adverse effects can include gastrointestinal symptoms, sleep changes, activation, sexual dysfunction, or other effects depending on medication. Starting, stopping, and changing medication should involve the prescribing clinician; abrupt discontinuation can produce withdrawal symptoms or destabilize mood. Prior bipolar symptoms require explicit assessment before antidepressant treatment. In a person with suicidal ideation or substantial clinical risk, arrange timely, more frequent assessment and appropriate specialist involvement. NICE NG222.
Combined care and stepped treatment
Psychotherapy and medication can be used together when depression severity, recurrence, preference, or incomplete response warrants a combined approach. Mild or less severe symptoms may initially be managed with active monitoring, structured psychological support, and carefully selected interventions; severe depression may require more intensive medication and psychological treatment, urgent assessment, or hospital-based care. Follow-up should check symptoms, everyday functioning, adherence, side effects, suicidality, and the trajectory of sleep and vasomotor problems. Treatment intensity is adjusted according to clinical need rather than a menopause label alone. NICE NG222.
Menopausal hormone therapy: what the evidence supports
Benefits for menopause symptoms
Systemic MHT is the most effective established treatment for troublesome vasomotor symptoms and may improve sleep disrupted by night sweats. The risk-benefit profile depends on age, time since the final menstrual period, route, formulation, duration, personal history, and medical contraindications. Individuals who retain a uterus generally require an appropriate progestogen with systemic estrogen to protect the endometrium; treatment after hysterectomy differs. Decisions should consider risks such as venous thromboembolism, stroke, and certain cancers according to individual circumstances. The Menopause Society 2022 hormone therapy statement.
Depressive symptoms versus diagnosed major depression
NICE distinguishes menopause-associated depressive symptoms that do not meet criteria for depression from a depressive disorder. It advises considering HRT for subthreshold depressive symptoms that begin around the same time as other menopause symptoms, and using depression-management guidance when clinical depression is suspected or diagnosed. This distinction preserves two evidence bases: menopause symptom treatment and psychiatric treatment. NICE NG23.
The 2018 expert guidelines concluded that antidepressants and psychotherapy were established first-line options for perimenopausal depression, while estrogen therapy showed possible antidepressant effects in some perimenopausal patients, especially those with vasomotor symptoms. Estrogen therapy is not approved as a general stand-alone treatment for major depression. Evidence about combined estrogen-progestogen regimens remains more complicated than evidence about treating hot flashes. Maki et al., 2019.
What did the 2026 meta-analysis find?
A 2026 systematic review and meta-analysis by Li and colleagues synthesized twelve randomized controlled trials of MHT among perimenopausal participants with depressive symptoms. Placebo-controlled comparisons suggested a small average reduction in depressive symptom severity (standardized mean difference −0.23, 95% CI −0.43 to −0.03). The authors rated certainty as limited and found insufficient evidence to confidently rank formulations or administration routes. These outcomes primarily concern symptom scales and heterogeneous study groups, so they do not demonstrate that MHT reliably produces remission of diagnosed major depressive disorder. Li et al., 2026.
Small randomized trials are relevant but should be interpreted in context. In an earlier twelve-week study involving fifty perimenopausal patients with depressive disorders, transdermal estradiol produced a higher remission rate than placebo; the sample was too small to settle broad questions about comparative effectiveness, safety, and long-term outcomes. Soares et al., 2001.
Another trial enrolled 172 initially nondepressed perimenopausal and early postmenopausal participants to evaluate prevention of depressive symptoms. During twelve months, 17.3% in the estradiol-plus-intermittent-progesterone group and 32.3% in the placebo group crossed the study's clinically significant symptom threshold. The outcome was a symptom-scale threshold, not proof of prevention of every diagnosed major depressive episode. Prevention findings from one trial are not a population-wide reason to prescribe hormones solely to avert depression. Gordon et al., 2018.
Clinical decision framework
A clinician may consider MHT when vasomotor symptoms are sufficiently burdensome and the person's medical profile supports its use. Mood effects can be monitored as an additional outcome. For diagnosed major depression, psychotherapy and/or appropriate antidepressant therapy remain central. Some individuals may receive both depression-directed care and MHT when indicated for menopause symptoms. MHT should never delay urgent mental health treatment, and psychiatric medication should not be stopped merely because hormone therapy begins. Individualized shared decisions and reassessment are essential. NICE NG23; The Menopause Society 2022 statement.
Other menopause treatments and their effects on mood
Nonhormonal interventions for hot flashes include certain SSRIs or SNRIs, gabapentin, and neurokinin-3 receptor antagonists, along with menopause-focused CBT. Their evidence for reducing vasomotor symptoms should not be mistaken for proof that each treats major depressive disorder. An intervention may improve sleep or daytime comfort, producing downstream mood benefits without acting as an antidepressant treatment. The Menopause Society 2023 statement.
Fezolinetant treats moderate-to-severe menopausal hot flashes and is not an approved antidepressant. The FDA added a boxed warning about rare but serious liver injury in December 2024, requiring baseline and follow-up liver testing under the current U.S. prescribing information. Any decision about this drug belongs to an individualized medical review. FDA safety communication.
Exercise, sleep routines, social connection, sufficient nutrition, reduced alcohol intake, and care for chronic illness can support general well-being and recovery. They may complement formal treatment but are not adequate substitutes for assessment of severe or persistent depressive illness. Nutritional supplements marketed as 'hormone balancing' or 'natural antidepressants' often lack convincing trial evidence, may interact with prescription medicines, and may distract from timely care. Recommendations should follow the outcome actually studied, rather than a broad wellness claim. NICE NG222; The Menopause Society 2023 statement.
Suicidal thinking, mania, psychosis, and urgent safety
Suicidal thoughts, intent, planning, or a recent attempt require prompt, direct clinical assessment. Severe hopelessness, inability to meet basic needs, psychotic symptoms, rapidly escalating agitation, or abrupt behavioral changes can also signal urgent risk. Ask clearly about suicidal thoughts rather than relying only on a questionnaire total. When there is immediate danger, use local emergency services or a nearby emergency department and remain with the person when it is safe to do so. In the United States, the 988 Suicide & Crisis Lifeline is available by call or text; elsewhere, use the corresponding local crisis service. NIMH, Depression; NICE NG222.
Mania can present with very little sleep but unusually high energy, pronounced behavioral activation, expansive or irritable mood, grandiosity, pressured speech, and unsafe decisions. Psychosis may involve delusions, hallucinations, or severe loss of reality testing. These presentations require urgent assessment and may demand emergency treatment. They are distinct from common hot flashes, anxiety, sleep deprivation, and ordinary emotional fluctuation. Assessment for bipolar disorder is especially important before initiating an antidepressant when a compatible history exists.
Postpartum psychosis is a separate reproductive psychiatric emergency occurring in the childbirth context; it must not be treated as a routine manifestation of perimenopause. A person who is recently postpartum and exhibits psychosis, mania, profound confusion, or danger to self or infant needs emergency psychiatric evaluation regardless of chronological age. Clinical risk follows symptoms and circumstance, not the chapter in which a condition is discussed.
Special clinical contexts
Surgical menopause, early menopause, and primary ovarian insufficiency
Removal of both ovaries, some medical treatments, and premature ovarian insufficiency can produce an abrupt or early alteration in ovarian hormone exposure. The relationship between symptoms and reproductive stage may differ from spontaneous perimenopause. Early menopause also carries specific concerns about fertility, bone health, cardiovascular risk, and identity. Treatment decisions can require a gynecologist or endocrinologist working alongside mental health specialists. NICE advises providing information and psychological support when menopause occurs early or after medical or surgical treatment. NICE NG23.
People with previous major depression
A prior episode may warrant a preventive follow-up plan during the transition. The plan can identify early signs of recurrence, maintain effective psychotherapy or medication when appropriate, address disrupted sleep, and specify when to seek review. Medication decisions should account for recurrence history and the consequences of discontinuation. A previous good response to a particular treatment can be informative, but the current clinical presentation remains decisive. Maki et al., 2019; NICE NG222.
Gender-diverse patients and individualized language
Not everyone who experiences menopause identifies as a woman. Some trans men and nonbinary people with ovaries can experience menopausal symptoms, although hormonal treatment, reproductive history, and distress may differ. A culturally responsive clinical interview uses the person's preferred language and assesses physiologic, psychological, and social needs without assuming a single life trajectory. NICE includes guidance for people registered female at birth who have used gender-affirming hormone therapy and now experience menopause-related symptoms. NICE NG23.
Barriers to timely care
Depressive symptoms in midlife may be overlooked when a patient or clinician attributes every change to 'normal hormones,' while menopause symptoms may be overlooked during psychiatric care. Coordinated services can help prevent both forms of underrecognition. Shared decisions are more effective when patients understand expected benefits, harms, practical costs, availability of treatments, and the possibility that different symptoms have different causes.
What recovery and follow-up can look like
Recovery is evaluated through improvement in mood and pleasure, restoration of everyday function, sleep quality, relationships, self-care, and safety. A patient may notice that night sweats improve before depression does, or that depressive thinking improves while hot flashes persist. These differences matter because they determine which part of treatment needs adjustment. Symptom review during the first weeks of a new antidepressant, with ongoing monitoring of adverse effects and suicidality, supports safe care. NICE NG222.
For persistent symptoms, the clinician should reconsider diagnosis, treatment adequacy, adherence, medical comorbidity, trauma exposure, bipolar features, and psychosocial stressors. Treatment changes can include a different evidence-based psychotherapy, a medication adjustment, combined treatment, or specialist consultation. Discontinuation planning should be gradual and collaborative, especially after recurrent episodes. Hormone therapy follow-up also requires reassessment of menopause symptoms, risks, bleeding patterns, and its separate treatment goals.
A useful personal record can include menstrual changes, hot flashes, sleep interruptions, daily mood and pleasure, activity, significant stressors, medication timing, and any suicidal thinking. Such a diary complements a clinical interview and can clarify temporal relationships without pretending that a chart proves causal mechanisms.
Evidence quality, open questions, and research priorities
Established evidence supports recognition of major depression using standard diagnostic principles and evidence-based psychotherapy and antidepressants when appropriate. Longitudinal observational research supports a higher average risk of depressive symptoms during the transition. Menopause-specific CBT and several medications have evidence for vasomotor-symptom relief, while systemic MHT is effective for hot flashes in medically eligible patients. These conclusions correspond to different treatment targets and should be evaluated separately. Badawy et al., 2024; NICE NG23; Maki et al., 2019.
Evidence for hormonal prevention or treatment of depressive symptoms remains preliminary to limited. Small trials demonstrate biologically plausible benefits in selected participants, and the 2026 synthesis found a modest mean benefit with uncertainty about comparative regimens and long-term safety. Research must distinguish diagnosed major depression from symptom-scale elevations, use consistent reproductive staging, examine long-term outcomes, and include more diverse participants. Mechanistic work should explain why some individuals appear sensitive to ovarian hormone fluctuation while others remain psychologically stable. Li et al., 2026; Gordon et al., 2018.
A central unresolved question is how strongly hormone variability, sleep disruption, life stress, and previous psychiatric vulnerability contribute to distinct depressive trajectories. Better repeated-measure studies can help identify who benefits from hormone treatment, who benefits primarily from depression-focused care, and when combined strategies improve outcomes. Scientific uncertainty on mechanisms should not prevent timely assessment and effective treatment now.
Frequently asked questions
Can perimenopause cause depression for the first time?
A first depressive episode can occur during perimenopause. The transition is associated with increased average risk, and some people may be sensitive to hormone fluctuations. A full assessment is still required because personal history, sleep, health conditions, medication effects, and stressful circumstances can also contribute. Badawy et al., 2024.
How long does perimenopausal depression last?
There is no single timetable. Duration depends on whether the individual has a depressive disorder, the course of menopausal symptoms, prior episodes, treatment access, and psychosocial conditions. Depression can improve during the transition with effective treatment and should not be left untreated in anticipation of the final menstrual period.
Will depression disappear after menopause?
Some people improve as symptoms change; others continue to experience depression into postmenopause. The 2024 pooled analysis found higher risk during perimenopause versus premenopause but no statistically significant elevation for postmenopause in its aggregated comparison. This population finding does not predict a person's individual course. Badawy et al., 2024.
Should estrogen be tested to diagnose depression?
No. Depression is assessed clinically, and a single estradiol or FSH test neither confirms nor excludes depressive illness. Perimenopause is often identified using menstrual and symptom history. Other tests are selected when there is a specific medical indication. STRAW+10; NICE NG23.
Is hormone therapy better than antidepressants?
They address partly different indications. Psychotherapy and antidepressants are established depression treatments. MHT is primarily used for eligible patients with troublesome menopause symptoms and may have additional mood effects. The 2026 meta-analysis found a small average symptom benefit from MHT, with limited certainty, and did not establish universal superiority to antidepressant or psychological treatment. Li et al., 2026; Maki et al., 2019.
Can depression medication and hormone therapy be used together?
For some patients, yes, when each has a clear indication and the prescribers review medical history, contraindications, interactions, and ongoing response. Neither treatment should be added or stopped automatically. Shared decision-making allows depression and menopause symptoms to be monitored as distinct outcomes.
Can night sweats alone explain low mood?
Night sweats can disrupt sleep and worsen daytime mood and energy, but persistent loss of interest, hopelessness, guilt, or functional impairment requires a direct depression assessment. Some patients benefit from treating both vasomotor symptoms and a coexisting depressive disorder.
When should someone seek immediate care?
Immediate care is indicated for current suicidal intent or planning, dangerous behavior, severe confusion, hallucinations, delusions, mania, or inability to remain safe. Contact emergency services in the relevant country. In the United States, 988 provides crisis support; urgent medical or psychiatric assessment is necessary when there is immediate danger. NIMH, Depression.
Related Articles
• Cluster Perinatal and Reproductive Mental Health — the central scientific chapter on reproductive mental health across the life course.
• Perinatal Mental Health: Conditions, Symptoms, Screening, and Care — an overview of assessment and psychiatric care during another major reproductive transition.
• Premenstrual Dysphoric Disorder: Symptoms, Diagnosis, and Treatment — cyclic mood symptoms and the distinction from sustained depressive illness.
References
Badawy, Y., Spector, A., Li, Z., & Desai, R. (2024). The risk of depression in the menopausal stages: A systematic review and meta-analysis. Journal of Affective Disorders, 357, 126–133. https://doi.org/10.1016/j.jad.2024.04.041.
Bromberger, J. T., Kravitz, H. M., Chang, Y.-F., Cyranowski, J. M., Brown, C., & Matthews, K. A. (2011). Major depression during and after the menopausal transition: Study of Women's Health Across the Nation. Psychological Medicine, 41, 1879–1888. https://doi.org/10.1017/S003329171100016X.
Gordon, J. L., Rubinow, D. R., Eisenlohr-Moul, T. A., Xia, K., Schmidt, P. J., & Girdler, S. S. (2018). Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: A randomized clinical trial. JAMA Psychiatry, 75, 149–157. https://doi.org/10.1001/jamapsychiatry.2017.3998.
Harlow, S. D., et al. (2012). Executive summary of the Stages of Reproductive Aging Workshop + 10: Addressing the unfinished agenda of staging reproductive aging. Journal of Clinical Endocrinology & Metabolism, 97, 1159–1168. https://doi.org/10.1210/jc.2011-3362.
Li, Y., Sun, Y., Bi, Y., Yang, L., Xu, Y., Wu, H., & Ma, X. (2026). Efficacy and safety of menopausal hormone therapy for depressive symptoms in perimenopausal women: A systematic review and meta-analysis. Journal of Affective Disorders, 409, 121892. https://doi.org/10.1016/j.jad.2026.121892.
Maki, P. M., et al. (2019). Guidelines for the evaluation and treatment of perimenopausal depression: Summary and recommendations. Journal of Women's Health, 28, 117–134. https://doi.org/10.1089/jwh.2018.27099.mensocrec.
National Institute for Health and Care Excellence (NICE). (2022). Depression in adults: Treatment and management (NG222). https://www.nice.org.uk/guidance/ng222/chapter/Recommendations.
National Institute for Health and Care Excellence (NICE). (2024, updated). Menopause: Identification and management (NG23). https://www.nice.org.uk/guidance/ng23/chapter/Recommendations.
National Institute of Mental Health (NIMH). (n.d.). Depression. https://www.nimh.nih.gov/health/publications/depression.
North American Menopause Society (The Menopause Society). (2022). The 2022 hormone therapy position statement. Menopause, 29, 767–794. https://doi.org/10.1097/GME.0000000000002028.
North American Menopause Society (The Menopause Society). (2023). The 2023 nonhormone therapy position statement. Menopause, 30, 573–590. https://doi.org/10.1097/GME.0000000000002200.
Soares, C. N., Almeida, O. P., Joffe, H., & Cohen, L. S. (2001). Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: A double-blind, randomized, placebo-controlled trial. Archives of General Psychiatry, 58, 529–534. https://doi.org/10.1001/archpsyc.58.6.529.
The Menopause Society. (n.d.). Mental health. https://menopause.org/patient-education/menopause-topics/mental-health.
U.S. Food and Drug Administration (FDA). (2024). FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause. https://www.fda.gov/drugs/drug-safety-communications/fda-adds-warning-about-rare-occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due.